Cristina Contini1, Davide Firinu2, Simone Serrao1, Barbara Manconi3, Alessandra Olianas1, Francesco Cinetto4, Fausto Cossu5, Massimo Castagnola6, Irene Messana7, Stefano Del Giacco2, Tiziana Cabras1. 1. Department of Life and Environmental Sciences, University of Cagliari, Cittadella Univ. Monserrato, ss 554, 09042, Monserrato, CA, Italy. 2. Department of Medical Sciences and Public Health, University of Cagliari, Cittadella Univ. Monserrato, Monserrato, 09042, CA, Italy. 3. Department of Life and Environmental Sciences, University of Cagliari, Cittadella Univ. Monserrato, ss 554, 09042, Monserrato, CA, Italy. bmanconi@unica.it. 4. Ca' Foncello Hospital - Treviso, Department of Medicine - DIMED, University of Padova, Padova, Italy. 5. Pediatric HSCT Unit, Pediatric Clinic of University, Ospedale Microcitemico, Cagliari, Italy. 6. Proteomics and Metabolomics Laboratory, IRCCS - Fondazione Santa Lucia, Rome, Italy. 7. CNR-SCITEC Istituto di Scienze e Tecnologie Chimiche, c/o Istituto di Biochimica e Biochimica Clinica Università Cattolica, L.go F. Vito, 1, 00168, Rome, Italy.
Abstract
PURPOSE: Present study is designed to discover potential salivary biomarkers associated with predominantly antibody deficiencies, which include a large spectrum of disorders sharing failure of antibody production, and B cell defects resulting in recurrent infections, autoimmune and inflammatory manifestations, and tumor susceptibility. Understanding and clinical classification of these syndromes is still challenging. METHODS: We carried out a study of human saliva based on liquid chromatography-mass spectrometry measurements of intact protein mass values. Salivary protein profiles of patients (n = 23) and healthy controls (n = 30) were compared. RESULTS: Patients exhibited lower abundance of α-defensins 1-4, cystatins S1 and S2, and higher abundance of glutathionylated cystatin B and cystatin SN than controls. Patients could be clustered in two groups on the basis of different levels of cystatin SN, S1 and S2, suggesting that these proteins may play different roles in the disease. CONCLUSIONS: Quantitative variations of these pro-inflammatory and antimicrobial peptides/proteins may be related to immunodeficiency and infectious condition of the patients. The high incidence of tumors in the group with the highest level of cystatin SN, which is recognized as tumoral marker, appeared an intriguing result deserving of future investigations. Data are available via ProteomeXchange with identifier PXD012688.
PURPOSE: Present study is designed to discover potential salivary biomarkers associated with predominantly antibody deficiencies, which include a large spectrum of disorders sharing failure of antibody production, and B cell defects resulting in recurrent infections, autoimmune and inflammatory manifestations, and tumor susceptibility. Understanding and clinical classification of these syndromes is still challenging. METHODS: We carried out a study of human saliva based on liquid chromatography-mass spectrometry measurements of intact protein mass values. Salivary protein profiles of patients (n = 23) and healthy controls (n = 30) were compared. RESULTS:Patients exhibited lower abundance of α-defensins 1-4, cystatins S1 and S2, and higher abundance of glutathionylated cystatin B and cystatin SN than controls. Patients could be clustered in two groups on the basis of different levels of cystatin SN, S1 and S2, suggesting that these proteins may play different roles in the disease. CONCLUSIONS: Quantitative variations of these pro-inflammatory and antimicrobial peptides/proteins may be related to immunodeficiency and infectious condition of the patients. The high incidence of tumors in the group with the highest level of cystatin SN, which is recognized as tumoral marker, appeared an intriguing result deserving of future investigations. Data are available via ProteomeXchange with identifier PXD012688.
Authors: Y V Chaly; E M Paleolog; T S Kolesnikova; I I Tikhonov; E V Petratchenko; N N Voitenok Journal: Eur Cytokine Netw Date: 2000-06 Impact factor: 2.737
Authors: T Suzuki; S Hashimoto; N Toyoda; S Nagai; N Yamazaki; H Y Dong; J Sakai; T Yamashita; T Nukiwa; K Matsushima Journal: Blood Date: 2000-10-01 Impact factor: 22.113
Authors: Emma Lindh; Johan Brännström; Petra Jones; Fredrik Wermeling; Signe Hässler; Corrado Betterle; Ben Zion Garty; Mats Stridsberg; Björn Herrmann; Mikael C I Karlsson; Ola Winqvist Journal: J Autoimmun Date: 2012-11-01 Impact factor: 7.094
Authors: Juan Antonio Vizcaíno; Attila Csordas; Noemi del-Toro; José A Dianes; Johannes Griss; Ilias Lavidas; Gerhard Mayer; Yasset Perez-Riverol; Florian Reisinger; Tobias Ternent; Qing-Wei Xu; Rui Wang; Henning Hermjakob Journal: Nucleic Acids Res Date: 2015-11-02 Impact factor: 16.971
Authors: Lorenzo Zallocco; Laura Giusti; Maurizio Ronci; Andrea Mussini; Marco Trerotola; Maria Rosa Mazzoni; Antonio Lucacchini; Laura Sebastiani Journal: Int J Mol Sci Date: 2021-04-21 Impact factor: 5.923
Authors: Michael A R Hollas; Matthew T Robey; Ryan T Fellers; Richard D LeDuc; Paul M Thomas; Neil L Kelleher Journal: Nucleic Acids Res Date: 2022-01-07 Impact factor: 16.971